86592
Syphilis Test; Qualitative (e.g., VDRL, RPR, ART)
CPT code 86592 describes a qualitative non-treponemal serologic test used for the screening and presumptive diagnosis of syphilis, an infection caused by the spirochete Treponema pallidum. Non-treponemal tests, such as the Rapid Plasma Reagin (RPR) and the Venereal Disease Research Laboratory (VDRL) test, do not detect the bacterium itself but rather measure reaginic antibodies (IgG and IgM) produced by the host in response to lipoidal material released from damaged host cells. These tests utilize an antigen suspension containing cardiolipin, lecithin, and cholesterol. When a patient's serum or plasma containing reagin antibodies is mixed with this antigen, a visible clumping or flocculation occurs, which is interpreted as a 'reactive' result. A 'non-reactive' result indicates no detectable antibodies at the time of testing. Because these tests are non-specific for Treponema pallidum, they are prone to biological false positives caused by other conditions such as systemic lupus erythematosus, acute viral infections, pregnancy, or recent vaccinations. Consequently, any reactive result obtained via CPT 86592 must be confirmed with a treponemal-specific test (e.g., 86780). The qualitative nature of 86592 means it provides a binary result (yes/no) rather than a titer. It is a cornerstone of public health screening programs, prenatal care protocols to prevent congenital syphilis, and the diagnostic workup for patients presenting with symptoms like painless chancres (primary syphilis) or diffuse rashes (secondary syphilis). While highly sensitive during the secondary stage of the disease, its sensitivity may be lower in the very early primary or late latent stages of infection.
Clinical Indications
- Routine screening for syphilis in high-risk populations.
- Mandatory prenatal screening during the first trimester of pregnancy.
- Evaluation of patients presenting with a primary chancre or unexplained genital lesions.
- Workup for patients with a generalized maculopapular rash involving palms and soles (secondary syphilis).
- Screening of blood, tissue, and organ donors.
- Assessment of individuals with known or suspected exposure to a sexual partner with syphilis.
- Diagnostic testing for patients with other sexually transmitted infections (STIs) due to high co-infection rates.
- Initial screening in patients presenting with neurologic or cardiovascular symptoms suggestive of late-stage syphilis.
Procedure Steps
- Obtain a peripheral venous blood sample from the patient using standard venipuncture technique.
- Centrifuge the blood sample to separate the serum or plasma from the cellular components.
- Prepare the antigen suspension (e.g., RPR charcoal-stabilized antigen or VDRL antigen).
- Place a measured aliquot of the patient's serum or plasma onto a disposable test card or glass slide.
- Add a standardized drop of the antigen suspension to the specimen.
- Rotate the card or slide mechanically (usually at 100 rpm) or manually for a specified duration (typically 8 minutes for RPR).
- Observe the mixture under a light source or microscope for the presence or absence of flocculation (clumping).
- Record the result as 'Reactive' if clumping is observed or 'Non-reactive' if the mixture remains smooth.
- Report the qualitative result to the ordering clinician.
Coding Guidelines
- Use 86592 for qualitative results only (e.g., reactive vs. non-reactive).
- If the laboratory performs a titration to determine the strength of the reaction (e.g., 1:64), use CPT 86593 instead.
- Do not report 86592 in conjunction with 86593 for the same specimen; the quantitative code (86593) includes the qualitative assessment.
- For treponemal-specific antibody tests (e.g., FTA-ABS, TP-PA), use CPT 86780.
- When syphilis testing is performed as part of a prenatal screen panel, refer to CPT 80055, which includes 86592.
- Ensure the medical record reflects the clinical necessity (e.g., symptoms or screening guidelines) to support the use of the code.